Comparative Pharmacology
Head-to-head clinical analysis: LEVOXYL versus TIROSINT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOXYL versus TIROSINT.
LEVOXYL vs TIROSINT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levothyroxine is a synthetic thyroid hormone (T4) that is deiodinated to triiodothyronine (T3) in peripheral tissues, binding to thyroid hormone receptors in the nucleus and increasing metabolic rate, protein synthesis, and oxygen consumption.
Tirosint is a synthetic form of levothyroxine (T4), which is converted to triiodothyronine (T3) in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription to increase metabolic rate, protein synthesis, and oxygen consumption.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 6-8 weeks based on TSH. Maintenance dose: 50-200 mcg orally once daily.
Initial dose 1.6 mcg/kg orally once daily, adjusted based on TSH levels. Typical maintenance dose 50-200 mcg/day.
None Documented
None Documented
6-7 days in euthyroid patients; prolonged in hypothyroidism (9-10 days), shortened in hyperthyroidism (3-4 days); clinical steady-state after 6-8 weeks of consistent dosing.
Terminal half-life approximately 7 days in euthyroid individuals; prolonged in hypothyroidism (up to 9-10 days) and shortened in hyperthyroidism (3-4 days). Clinical context: steady-state reached in 4-6 weeks; dosage adjustments require 6-8 weeks for full effect.
Renal (30-50% as unchanged drug and conjugates); fecal (biliary, 20-40% as conjugates); total clearance approximates 1-2 L/day in euthyroid patients.
Renal (approximately 30-40% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates); fecal (approximately 20-30% via bile); total clearance is low (~0.05 L/hr/kg).
Category C
Category C
Thyroid Hormone
Thyroid Hormone